Walleye Capital’s Bicara Therapeutics BCAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.25M Sell
282,138
-71,088
-20% -$1.78M ﹤0.01% 1845
2026
Q2
$10.5M Buy
353,226
+245,218
+227% +$5.47M 0.04% 457
2026
Q1
$2.15M Buy
+108,008
New +$1.86M 0.01% 1412
2025
Q3
– Sell
-24,308
Closed -$226K – 5263
2025
Q2
$226K Buy
+24,308
New +$290K ﹤0.01% 3265
2024
Q4
– Sell
-31,780
Closed -$809K – 5727
2024
Q3
$809K Buy
+31,780
New +$810K ﹤0.01% 2856

Other funds holding BCAX

Walleye Capital's BCAX Position: Q3 2026 in Review

Walleye Capital reduced its Bicara Therapeutics (BCAX) stake by 20% in Q3 2026, selling an estimated $1.78M and leaving 282,138 shares worth $5.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1845.

Walleye Capital first reported a position in BCAX in Q3 2024 and has held it in 5 quarters since. The position peaked at $10.5M in Q2 2026. 167 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

  • Walleye Capital held 282,138 shares of Bicara Therapeutics worth $5.25M as of Q3 2026.
  • Walleye Capital sold 71,088 Bicara Therapeutics shares in Q3 2026, an estimated $1.78M.
  • Bicara Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #1845 holding.
  • Walleye Capital first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Walleye Capital's Bicara Therapeutics position peaked at $10.5M in Q2 2026.
  • 167 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.